摘要
目的探讨最大限度经尿道膀胱肿瘤电切术(trans urethral resection of bladder tumor,TURBT)后,辅助免疫治疗联合化疗对肌层浸润性膀胱癌(muscle-invasive bladder cancer,MIBC)患者的疗效。方法目的选取2021年5月—2024年1月京东誉美中西医结合肾病医院收治的121例MIBC患者作为研究对象,根据治疗方式不同分为观察组(60例)和对照组(61例),两组患者均采用TURBT术治疗,在此基础上,对照组应用化疗治疗,观察组采用免疫治疗联合化疗治疗。对比两组复发情况、生存情况、不良反应发生情况及生活质量。结果术后6个月,观察组的复发率为10.00%(6/60),低于对照组的24.59%(15/61),差异有统计学意义(χ^(2)=4.489,P<0.05)。观察组总生存率高于对照组,差异有统计学意义(χ^(2)=7.341,P<0.05)。观察组膀胱刺激征、血尿发生率低于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组生活质量评分低于对照组,差异均有统计学意义(P均<0.05)。结论最大限度TURBT术后辅助免疫治疗联合化疗在MIBC患者中疗效显著,延长了无进展生存期和总生存期,并降低了肿瘤复发率患者生活质量得到改善。
Objective To investigate the efficacy of adjuvant immunotherapy combined with chemotherapy in patients with muscle-invasive bladder cancer(MIBC)after transurethral resection of bladder tumor(TURBT).Methods A total of 121 MIBC patients admitted to Jingdong Yumei Integrated Traditional Chinese and Western Medicine Kidney Dis-ease Hospital from May 2021 to January 2024 were purposefully selected as the research objects.According to different treatment methods,they were divided into observation group(60 cases)and control group(61 cases).Both groups were treated with TURBT.On this basis,the control group was treated with chemotherapy,and the observation group was treated with immunotherapy combined with chemotherapy.The recurrence,survival,adverse reactions and quality of life were compared between the two groups.Results At 6 months after operation,the recurrence rate of the observa-tion group was 10.00%(6/60),which was lower than 24.59%(15/61)of the control group,and the difference was statis-tically significant(χ^(2)=4.489,P<0.05).The overall survival rate of the observation group were higher than those of the control group,and the differences were statistically significant(χ^(2)=7.341,P<0.05).The incidence of bladder irritation and hematuria in the observation group was lower than that in the control group,and the differences were statistically significant(all P<0.05).After treatment,the quality of life scale score of the observation group was lower than that of the control group,and the differences were statistically significant(all P<0.05).Conclusion Adjuvant immunotherapy combined with chemotherapy after maximum TURBT showed significant efficacy in MIBC patients,the progression-free survival and overall survival were prolonged,the tumor recurrence rate was reduced,and the quality of life of pa-tients was improved.
作者
孙浩洋
李宝龙
秦伟
SUN Haoyang;LI Baoong;QIN Wei(Department of Urology,Jingdong Yumei Integrated Traditional Chinese and Western Medicine Kidney Disease Hospital,Sanhe 065201,Hebei,China)
出处
《系统医学》
2025年第12期165-169,共5页
Systems Medicine
